Caris Life Sciences (CAI) Total Debt (2024 - 2026)

Caris Life Sciences' Total Debt history runs 3 years deep, the most recent figure standing at $381.2 million for Q1 2026.

• On a quarterly basis, Total Debt changed N/A year-over-year to $381.2 million in Q1 2026; TTM through Mar 2026 was $381.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $379.0 million, down 12.52% from the prior year.
• Total Debt rose to $381.2 million in Q1 2026 per CAI's latest filing, from $379.0 million in the prior quarter.
• Across five years, Total Debt topped out at $433.2 million in Q4 2024 and bottomed at $373.5 million in Q2 2025.
• The 3-year median for Total Debt is $379.0 million (2025), against an average of $388.6 million.
• Biggest YoY gain for Total Debt was 12.52% in 2025; the steepest drop was 12.52% in 2025.
• Year by year, Total Debt stood at $433.2 million in 2024, then decreased by 12.52% to $379.0 million in 2025, then climbed by 0.59% to $381.2 million in 2026.
• Per Business Quant, the three latest CAI Total Debt figures stand at $381.2 million (Q1 2026), $379.0 million (Q4 2025), and $376.0 million (Q3 2025).